NCT02856802View on ClinicalTrials.gov

An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

July 11, 2016

Primary Completion Date

February 10, 2017

Study Completion Date

February 10, 2017

Conditions
Migraine Headaches
Interventions
DRUG

Sumatriptan 10 mg Nasal Spray

100 μL nasal spray once

OTHER

Sumatriptan Placebo Nasal Spray

100 μL nasal spray once

Trial Locations (9)

14221

Site 25, Williamsville

14609

Site 29, Rochester

29464

Site 33, Mt. Pleasant

48104

Site 18, Ann Arbor

84088

Site 28, West Jordan

87102

Site 02, Albuquerque

90404

Site 11, Santa Monica

92108

Site 30, San Diego

02131

Site 31, Boston

All Listed Sponsors
lead

Upsher-Smith Laboratories

INDUSTRY

NCT02856802 - An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg) | Biotech Hunter | Biotech Hunter